

ASX RELEASE (6 May 2025)

## **Epsilon Healthcare announces renewal of Medicinal Cannabis Permit**

Epsilon Healthcare (**ASX: EPN**) (Epsilon or the Company), a leading company in Pharmaceutical Contract Development and Manufacturing, Telehealth & Pharmacy services, is pleased to announce that its onshore Pharmaceutical Contract Development and Manufacturing subsidiary, Epsilon Pharma Pty Ltd, has been granted a renewal of its Medicinal Cannabis Permit.

### **Highlights**

- **The DoHA Office of Drug Control (ODC) issues Epsilon Pharma a renewal of its Medicinal Cannabis Permit;**
- **The Medicinal Cannabis Permit is for the manufacture of a cannabis drug for one of more permitted supplies;**
- **The allowable manufacturing quantities in the approved permit are an increase on previous permits reflecting the increased activities by Epsilon Pharma for the upcoming twelve months;**
- **The increased quantities reflect an increased demand for onshore GMP manufacturing services;**
- **The approval grants Epsilon Pharma with an export licence;**
- **The approval grants Epsilon Pharma with an import permit.**

### **Overview of Epsilon Pharma onshore manufacturing operations**

Epsilon Pharma Pty Ltd is the wholly owned Contract Development and Manufacturing subsidiary of Epsilon Healthcare Limited. It is an Australian domiciled and globally active commercial Contract Development and Manufacturing Organisation (CDMO). Its state of the art facility, located in Southport Queensland, is approved by the Therapeutic Goods Administration (TGA) and ODC to manufacture products in strict accordance with the code of Good Manufacturing Practice (GMP). Epsilon Pharma is a leader in the field of extraction processes, with the Southport facility possessing a large-scale capacity to deliver contract or toll manufacturing services to a diverse range of clients.

Epsilon Pharma is licensed to undertake the full manufacture of a diverse range of oral liquids, dried herbs, vapourised finished products and an ability to bring any oil formulation in-house. The imminent addition of the automated edibles manufacturing line will further enhance Epsilon Pharma's manufacturing capabilities.

The Epsilon Pharma operation is also licensed to undertake full product manufacture of Active Pharmaceutical Ingredients (APIs) including the extraction of biomass and extraction of crude extracts including the manufacture of distillates and sought after isolates.

The highly skilled Epsilon Pharma team including in-house QC & QA functions have been developing and manufacturing products for the local and international markets since 2018. The in-house Research & Development (R&D) and Manufacturing Science & Technologies (MSAT) team allows the business to support clients in the development of custom and bespoke formulations and specialised product needs.

The Epsilon Healthcare Group CEO & Managing Director, Peter Giannopoulos said “The successful renewal of the Medicinal Cannabis Permit for manufacture of cannabis finished products reflects the dedication of the Southport team to the delivery of a high-quality end to end manufacturing service for Australian and international clients. The vastly expanded manufacturing quantities allowed for in the permit is the result of a planned increased manufacturing activities & reflects the commitment of our Pharma subsidiary and Epsilon Healthcare to be leaders in the medicinal cannabis ecosystem and healthcare more broadly. The ongoing investment in building expanded teams and a diversified product manufacturing offering, including GMP manufactured edibles will support the organisation in becoming a valuable stakeholder in the expanding and diverse healthcare landscape. The Board of Epsilon Healthcare is committed to the diversification of operations and service offerings, in addition to delivering innovation by fostering the development of new products and services which meet evolving client, patient and consumer needs”.

The Announcement has been approved by the full Board of the Company

Alan Beasley  
Chairman

ENDS

For further information, please contact:

Peter Giannopoulos  
Group Chief Executive Officer & Managing Director  
e: [corporate@epsilonhealthcare.com.au](mailto:corporate@epsilonhealthcare.com.au)





Epsilon Healthcare Limited (ASX: EPN) – [epsilonhealthcare.com.au](http://epsilonhealthcare.com.au)

Epsilon Healthcare Limited (**ASX: EPN**) is an Australian based, globally active healthcare organisation. EPN operates a diversified and vertically integrated portfolio of assets, including healthcare and clinics operation, pharmaceutical contract development and manufacture & pharmacy dispensing and information services.

